Treatment compositions comprising microcapsules, primary or secondary amines, and formaldehyde scavengers

ABSTRACT

The need for a treatment composition which provides a pleasant odor to a treated situs, particularly one having a long-lasting woody, floral, fruity or citrus character, and which does not discolor over time, is met by formulating the treatment composition with microcapsules comprising a microcapsule wall formed from cross-linked formaldehyde, and a core comprising an aldehyde or ketone containing perfume, in combination with a formaldehyde scavenger which does not complex with the aldehyde and/or ketone and amine, to form complexes that result in discoloration.

FIELD OF THE INVENTION

Treatment compositions comprising perfume containing microcapsules andformaldehyde scavengers which do not comprise an activated methylenegroup, can provide a prolonged odour benefit without exhibitingdiscoloration.

BACKGROUND OF THE INVENTION

Perfume raw materials, selected from aldehydes, ketones, and mixturesthereof, are typically used to provide woody, floral, fruity or citrusnotes to treatment compositions, and to substrates treated by suchcompositions. They are also highly preferred, since they provide anodour benefit at low concentrations. It is desirable to encapsulate suchaldehydes and ketones into microcapsules, in order to provide longlasting, or in-use odour benefits.

Such microcapsules are typically made by cross-linking selected monomerstogether, in order to form a shell around a core material, whichcomprises the perfume raw materials to be encapsulated. Formaldehyde isa preferred monomer, in combination with another monomer which iscapable of forming a cross-linked polymer network with formaldehyde.However, such microcapsules are known to slowly release freeformaldehyde. In addition, residual amounts of formaldehyde typicallyremain after the microcapsules are formed. As a result, a formaldehydescavenger is usually added to the treatment composition, to keep theformaldehyde level to within acceptable levels.

It has been found that treatment compositions containing such perfumemicrocapsules have poor colour stability. Moreover, the microcapsuleslurries themselves often also exhibit poor colour stability. Therefore,a need remains for a treatment composition, particularly one thatprovides a long-lasting woody, floral, fruity or citrus character to thetreated substrate, comprising microcapsules, while also having goodcolour stability.

SUMMARY OF THE INVENTION

The present invention relates to a treatment composition comprising:microcapsules, the microcapsules comprising a microcapsule core and amicrocapsule wall which encapsulates the microcapsule core, wherein themicrocapsule wall is formed by cross-linking formaldehyde with at leastone other monomer; and the microcapsule core comprises a perfume, theperfume comprising a perfume raw material selected from the groupconsisting of aldehydes, ketones, and mixtures thereof; and aformaldehyde scavenger selected from the group consisting of: urea,pyrogallol, 1,2 hexanediol, and mixtures thereof.

The present invention further relates a unit dose article, comprisingsuch treatment compositions, wherein the treatment composition comprisesless than 20% by weight of water, and the treatment composition isenclosed in a water-soluble or dispersible film.

The present invention further relates to the use of a formaldehydescavenger selected from the group consisting of: urea, pyrogallol, 1,2hexanediol, and mixtures thereof, for preventing discoloration in atreatment composition comprising microcapsules.

The present invention further relates to a method of providing anextended odour benefit to a situs, by contacting the situs with atreatment composition according to the present invention.

DETAILED DESCRIPTION OF THE INVENTION

The treatment compositions of the present invention have improved colourstability. By encapsulating a perfume composition comprising perfumealdehydes and ketones, in a microcapsule that is formed by cross linkingformaldehyde with another monomer, a long lasting perfume note, and inparticular, a woody, floral, fruity or citrus note, can be provided bythe treatment composition comprising the perfume microcapsules.

It is believed that residual amounts of the perfume raw materials,including the aldehydes and ketones, remain unencapsulated. In addition,due to porosity of the microcapsule walls, the perfume raw materials areable to slowly leak from the microcapsules, thereby increasing the levelof unencapsulated aldehydes and ketones that are present in thetreatment composition.

In addition, residual levels of free formaldehyde remain after themicrocapsule making process and are incorporated thereafter into thetreatment composition. Moreover, formaldehyde is also slowly releasedfrom the microcapsule walls.

Many of the formaldehyde scavengers that are typically used inmicrocapsule containing treatment compositions, such as aceoacetamide,acetoacetic acid ethyl ester, and malonamide, comprise an activatedmethylene group. However, the perfume aldehydes and ketones may formcoloured complexes with such formaldehyde scavengers, and primary orsecondary amines, altering the composition colour. Similarly, perfumealdehydes and ketones which are added, as part of an unencapsulatedperfume, to the treatment composition also complex with theaforementioned formaldehyde scavengers, and primary or secondary amine.The coloured complexes result in an often undesirable change to theoriginal colour of the treatment composition, resulting indiscolouration. The present Applicants have found that suchdiscoloration is avoided through the use of urea, pyrogallol, 1,2hexanediol, and mixtures thereof, as formaldehyde scavengers. It isbelieved that, since they do not comprise an activated methylene group,they are unable to react with perfume aldehydes and ketones, to formcoloured compounds which discolour the treatment composition.

As defined herein, “essentially free of” a component means that thecomponent is present at a level of less that 15%, preferably less 10%,more preferably less than 5%, even more preferably less than 2% byweight of the respective slurry or composition. Most preferably,“essentially free of” a component means that no amount of that componentis present in the respective slurry, or composition.

As defined herein, “stable” means that no visible phase separation isobserved for a slurry or treatment composition kept at 25° C. for aperiod of at least two weeks, or at least four weeks, or at least fourmonths, as measured using the Floc Formation Test, described in USPA2008/0263780 A1. Colour stable means that there is no observable changein colour for a slurry or treatment composition, in comparison tofreshly made slurry or treatment composition, when the slurry ortreatment composition is kept at 40° C. for a period of at least twoweeks, or at least four weeks, or at least four months.

All percentages, ratios and proportions used herein are by weightpercent of the respective slurry or composition, unless otherwisespecified. All average values are calculated “by weight” of therespective slurry, composition, or components thereof, unless otherwiseexpressly indicated. All measurements are performed at 25° C. unlessotherwise specified.

Unless otherwise noted, all component, slurry, or composition levels arein reference to the active portion of that component, slurry, orcomposition, and are exclusive of impurities, for example, residualsolvents or by-products, which may be present in commercially availablesources of such components or compositions.

The Treatment Composition:

The treatment composition comprises microcapsules for providing along-lasting in-use odour benefit. The microcapsules are typically addedto the treatment composition as part of a microcapsule slurry. Thetreatment composition preferably comprises the microcapsules at a levelof from 0.01 wt % to 12.5 wt %, preferably from 0.1 wt % to 2.5 wt %,more preferably from 0.15 wt % to 1 wt % by weight of the treatmentcomposition. The treatment compositions preferably comprise themicrocapsules at a level, such that perfume, which is comprised in themicrocapsule core, is present in the treatment composition at a level offrom 0.01 wt % to 10 wt %, preferably from 0.1 wt % to 2 wt %, morepreferably from 0.15 wt % to 0.75 wt % by weight of the treatmentcomposition.

Since the perfume contained within the microcapsules is encapsulated bythe microcapsule walls, they do not provide significant odour benefit tothe treatment composition itself. As such, an unencapsulated perfumecomposition is typically added to the treatment composition. Whenpresent, the treatment composition typically comprises theunencapsulated perfume at a level of from 0.1% to 5%, more preferablyfrom 0.3% to 3%, even more preferably from 0.6% to 2% by weight of thetreatment composition.

In order to have a similar character to the perfume comprised on themicrocapsule core, the unencapsulated perfume composition preferablycomprises a perfume raw material selected from the group consisting of:an aldehyde, a ketone, and mixtures thereof. Even more preferably, theunencapsulated perfume comprises a perfume raw material selected fromthe group consisting of: an aldehyde, a ketone, and mixtures thereof, ata level of from 0.1% to 100%, even more preferably from 1% to 50% byweight of the unencapsulated perfume. The aldehydes and ketonescomprised in the unencapsulated perfume also do not complex with theformaldehyde scavengers of the present invention, to form complexes thatresult in discoloration.

Suitable treatment compositions include: products for treating fabrics,including laundry detergent compositions and rinse additives; hardsurface cleaners including dishwashing compositions, floor cleaners, andtoilet bowl cleaners.

Fabric treatment compositions are particularly preferred. As usedherein, “fabric treatment composition” refers to any composition capableof cleaning a fabric, or providing a fabric care benefit, e.g., onclothing, in a domestic washing machine. Such fabric treatmentcompositions can be selected from the group consisting of: laundrydetergent compositions, fabric softening compositions, and combinationsthereof. During machine washing of fabrics, laundry detergentcompositions are typically added to the wash cycle, while fabricsoftening compositions are typically added during the rinse cycle.

The composition can be in solid form, such as powders or granules.However, the treatment composition is preferably a fluid treatmentcomposition. As used herein, “fluid treatment composition” refers to anytreatment composition comprising a fluid capable of wetting and treatinga substrate, such as fabric or hard surface. Fluid treatmentcompositions are particularly preferred, since they are more readilydispersible, and can more uniformly coat the surface to be treated.Fluid treatment compositions can flow at 25° C., and includecompositions that have an almost water like viscosity, but also include“gel” compositions that flow slowly and hold their shape for severalseconds or minutes.

A suitable fluid composition can include solids or gases in suitablysubdivided form, but the overall composition excludes product formswhich are non-fluid overall, such as tablets or granules. The fluidcompositions preferably have densities in the range from of 0.9 to 1.3grams per cubic centimeter, more preferably from 1.00 to 1.10 grams percubic centimeter, excluding any solid additives but including anybubbles, if present.

The fluid composition may be a dilute or concentrated liquid.Preferably, the fluid composition comprises from 1% to 95% by weight ofwater and/or non-aminofunctional organic solvent. For concentrated fluidcompositions, the composition preferably comprises from 15% to 70%, morepreferably from 20% to 50%, most preferably from 25% to 45% by weight ofwater, non-aminofunctional organic solvent, and mixtures thereof.Alternatively, the treatment composition may be a low water fluidcomposition. Such low water fluid compositions can comprise less than20%, preferably less than 15%, more preferably less than 10% by weightof water.

The fluid composition of the present invention may also comprise from 2%to 40%, more preferably from 5% to 25% by weight of anon-aminofunctional organic solvent. Non-aminofunctional organicsolvents are organic solvents which contain no amino functional groups.Preferred non-aminofunctional organic solvents include monohydricalcohols, dihydric alcohols, polyhydric alcohols, glycerol, glycolsincluding polyalkylene glycols such as polyethylene glycol, and mixturesthereof. More preferred non-aminofunctional organic solvents includemonohydric alcohols, dihydric alcohols, polyhydric alcohols, glycerol,and mixtures thereof. Highly preferred are mixtures ofnon-aminofunctional organic solvents, especially mixtures of two or moreof the following: lower aliphatic alcohols such as ethanol, propanol,butanol, isopropanol; diols such as 1,2-propanediol or 1,3-propanediol;and glycerol. Also preferred are mixtures of propanediol and diethyleneglycol. Such mixtures preferably contain no methanol or ethanol.

Preferable non-aminofunctional organic solvents are liquid at ambienttemperature and pressure (i.e. 21° C. and 1 atmosphere), and comprisecarbon, hydrogen and oxygen. Non-aminofunctional organic solvents may bepresent when preparing a premix, or in the final fluid composition.

The treatment composition can also be encapsulated in a water solublefilm, to form a unit dose article. Such unit dose articles comprise atreatment composition of the present invention, wherein the treatmentcomposition comprises less than 20%, preferably less than 15%, morepreferably less than 10% by weight of water, and the treatmentcomposition is enclosed in a water-soluble or dispersible film. Suchunit-dose articles can be formed using any means known in the art. Unitdose articles comprising a laundry detergent composition areparticularly preferred.

Suitable water soluble pouch materials include polymers, copolymers orderivatives thereof. Preferred polymers, copolymers or derivativesthereof are selected from the group consisting of: polyvinyl alcohols,polyvinyl pyrrolidone, polyalkylene oxides, acrylamide, acrylic acid,cellulose, cellulose ethers, cellulose esters, cellulose amides,polyvinyl acetates, polycarboxylic acids and salts, polyaminoacids orpeptides, polyamides, polyacrylamide, copolymers of maleic/acrylicacids, polysaccharides including starch and gelatin, natural gums suchas xanthum and carragum. More preferred polymers are selected frompolyacrylates and water-soluble acrylate copolymers, methylcellulose,carboxymethylcellulose sodium, dextrin, ethylcellulose, hydroxyethylcellulose, hydroxypropyl methylcellulose, maltodextrin,polymethacrylates, and most preferably selected from polyvinyl alcohols,polyvinyl alcohol copolymers and hydroxypropyl methyl cellulose (HPMC),and combinations thereof.

Since the treatment compositions and unit dose articles, of the presentinvention, maintain their colour over longer periods of time, they canbe packaged within transparent or translucent containers, whilemaintaining an aesthetically pleasing appearance. Translucent containersare containers having sufficient transparency, that the colour of thecontained composition or unit dose articles can be seen.

A) Detergent Compositions:

The treatment composition of the present invention can be a detergentcomposition, preferably a laundry detergent composition. Detergentcompositions comprise a surfactant, to provide a detergency benefit. Thedetergent compositions of the present invention may comprise from 1% to70%, preferably from 5% to 60%, more preferably from 10% to 50%, mostpreferably from 15% to 45% by weight of a surfactant selected from thegroup consisting of: anionic, nonionic surfactants and mixtures thereof.The preferred weight ratio of anionic to nonionic surfactant is from100:0 (i.e. no nonionic surfactant) to 5:95, more preferably from 99:1to 1:4, most preferably from 5:1 to 1.5:1.

The detergent compositions of the present invention preferably comprisefrom 1 to 50%, more preferably from 5 to 40%, most preferably from 10 to30% by weight of one or more anionic surfactants. Preferred anionicsurfactant are selected from the group consisting of: C11-C18 alkylbenzene sulphonates, C10-C20 branched-chain and random alkyl sulphates,C10-C18 alkyl ethoxy sulphates, mid-chain branched alkyl sulphates,mid-chain branched alkyl alkoxy sulphates, C10-C18 alkyl alkoxycarboxylates comprising 1-5 ethoxy units, modified alkylbenzenesulphonate, C12-C20 methyl ester sulphonate, C10-C18 alpha-olefinsulphonate, C6-C20 sulphosuccinates, and mixtures thereof. However, bynature, every anionic surfactant known in the art of detergentcompositions may be used, such as those disclosed in “Surfactant ScienceSeries”, Vol. 7, edited by W. M. Linfield, Marcel Dekker. The detergentcompositions preferably comprise at least one sulphonic acid surfactant,such as a linear alkyl benzene sulphonic acid, or the water-soluble saltform of the acid.

The detergent compositions of the present invention preferably compriseup to 30%, more preferably from 1 to 15%, most preferably from 2 to 10%by weight of one or more nonionic surfactants. Suitable nonionicsurfactants include, but are not limited to C12-C18 alkyl ethoxylates(“AE”) including the so-called narrow peaked alkyl ethoxylates, C6-C12alkyl phenol alkoxylates (especially ethoxylates and mixedethoxy/propoxy), block alkylene oxide condensate of C6-C12 alkylphenols, alkylene oxide condensates of C8-C22 alkanols and ethyleneoxide/propylene oxide block polymers (Pluronic®-BASF Corp.), as well assemi polar nonionics (e.g., amine oxides and phosphine oxides). Anextensive disclosure of suitable nonionic surfactants can be found inU.S. Pat. No. 3,929,678.

The detergent composition may also include conventional detergentingredients selected from the group consisting of: additionalsurfactants such as amphoteric, zwitterionic, cationic surfactant, andmixtures thereof; enzymes; enzyme stabilizers; amphiphilic alkoxylatedgrease cleaning polymers; clay soil cleaning polymers; soil releasepolymers; soil suspending polymers; bleaching systems; opticalbrighteners; hueing dyes; particulate material; perfume and other odourcontrol agents, including perfume delivery systems; hydrotropes; sudssuppressors; fabric care perfumes; pH adjusting agents; dye transferinhibiting agents; preservatives; non-fabric substantive dyes; andmixtures thereof.

B) Fabric Softening Compositions:

The treatment composition can be a fabric softening composition. Suchfabric softening compositions comprise a fabric softening active(“FSA”). Suitable fabric softening actives include materials selectedfrom the group consisting of quats, amines, fatty esters, sucroseesters, silicones, dispersible polyolefins, clays, polysaccharides,fatty oils, polymer latexes and mixtures thereof.

Suitable quats include materials selected from the group consisting ofester quats, amide quats, imidazoline quats, alkyl quats, amidoesterquats and mixtures thereof. Suitable ester quats include materialsselected from the group consisting of monoester quats, diester quats,triester quats and mixtures thereof. Suitable amide quats includematerials selected from the group consisting of monoamide quats, diamidequats and mixtures thereof. Suitable alkyl quats include materialsselected from the group consisting of mono alkyl quats, dialkyl quats,trialkyl quats, tetraalkyl quats and mixtures thereof.

Suitable amines include materials selected from the group consisting ofesteramines, amidoamines, imidazoline amines, alkyl amines, amdioesteramines and mixtures thereof. Suitable ester amines include materialsselected from the group consisting of monoester amines, diester amines,triester amines and mixtures thereof. Suitable amido quats includematerials selected from the group consisting of monoamido amines,diamido amines and mixtures thereof. Suitable alkyl amines includematerials selected from the group consisting of mono alkylamines,dialkyl amines quats, trialkyl amines, and mixtures thereof.

In a preferred embodiment, the FSA is a quaternary ammonium compound.Quaternary ammonium compounds are typically formed from a reactionproduct of a fatty acid and an aminoalcohol, obtaining mixtures ofmono-, di-, and, optionally tri-ester compounds. The FSA may compriseone or more softener quaternary ammonium compounds such as thoseselected from the group consisting of: a mono-alkyl quaternary ammoniumcompound, di-alkyl quaternary ammonium compound, a di-amido quaternarycompound, a di-ester quaternary ammonium compound, and mixtures thereof.More preferably, the FSA comprises the di-ester quaternary ammoniumcompound (hereinafter referred to as “DQA”). Even more preferably, theFSA comprises a protonated DQA.

Examples of suitable FSAs, and compositions comprising them, can befound in US 2004/0204337 A1, US 2004/0229769 A1, and U.S. Pat. No.6,494,920.

The fabric softening composition preferably comprises the FSA a level ofat least 2%, more preferably at least about 5%, even more preferably atleast about 10%, most preferably at least about 10% by weight of thecomposition. The fabric care composition preferably comprises the FSA ofa level of less than 40%, more preferably less than 30%, most preferablyless than 20%, by weight of the composition.

The fabric softening composition may comprise additional softeningadditives, selected from the group consisting of: polysaccharide,silicone, sucrose ester, dispersible polyolefin, polymer latex, fattyacid, softening oils, clays, and mixtures thereof.

The fabric softening composition may comprise an adjunct ingredient,such as those selected from the group consisting of: colorants,brighteners, soil release polymers, preservatives, static controlagents, soil release agents, malodour control agents, fabric refreshingagents, colour maintenance agents, whiteness enhancers, anti-abrasionagents, and mixtures thereof.

Microcapsules:

The treatment composition comprises microcapsules. The microcapsulescomprise a microcapsule core and a microcapsule wall that surrounds themicrocapsule core. The microcapsule wall is formed by cross-linkingformaldehyde with at least one other monomer. The term “microcapsule” isused herein in the broadest sense to include a core that is encapsulatedby the microcapsule wall. In turn, the microcapsule core comprises aperfume. The encapsulated perfume comprises a perfume raw materialselected from aldehydes, ketones, and mixtures thereof, and optionally adiluent.

Diluents are materials used to dilute the perfume that is encapsulated,and are hence preferably inert. That is, they do not react with theperfume during making or use. Preferred diluents may be selected fromthe group consisting of: isopropyl myristate, propylene glycol,poly(ethylene glycol), or mixtures thereof.

The microcapsules are typically formed by emulsifying the core material,comprising the perfume, into droplets and polymerizing the wall materialaround the droplets. As a result, the microcapsules are usuallyavailable as part of a slurry. The microcapsule slurry will typicallycomprise further ingredients, such as anionic emulsifiers, stabilizerssuch as magnesium chloride, and preservatives. Encapsulation techniquesare disclosed in MICROENCAPSULATION: Methods and IndustrialApplications, Edited by Benita and Simon (Marcel Dekker, Inc., 1996).Formaldehyde based resins such as melamine-formaldehyde orurea-formaldehyde resins are especially attractive for perfumeencapsulation due to their wide availability and reasonable cost.

A preferred method for forming microcapsule walls is polycondensation,which may be used to produce aminoplast encapsulates. Aminoplast resinsare the reaction products of one or more amine comprising monomer, withone or more aldehydes, formaldehyde being the aldehyde of choice for thepresent invention. The shell material surrounding the core to form themicrocapsule can be formed by cross-linking the formaldehyde with atleast one other monomer. While any suitable monomer may be used, the atleast one other monomer is preferably selected from the group consistingof: melamine and its derivatives, urea, thiourea, glycouril,benzoguanamine, acetoguanamine, dihydroxyethyleneurea, hydroxy (alkoxy)alkyleneurea monomers, and mixtures thereof. Any suitable process can beused to form such aminoplast encapsulates. Examples of suitableprocesses can be found in U.S. Pat. No. 3,516,941.

The microcapsule slurry can be refined to remove polymerized wallmaterial residues, which do not comprise any perfume, in addition to anyunreacted polymer. Methods of refining the slurry includecentrifugation, for instance, using a disc stack centrifuge. Suitablemethods of refining the microcapsule slurry can be found in USPA2010/0029539 A1.

The microcapsule wall may be coated with one or more materials, such asa deposition polymer, that aids in the deposition and/or retention ofthe microcapsule on the site that is treated with compositionscomprising the microcapsules. Suitable deposition polymers are typicallycationic, and can be selected from the group consisting of:polysaccharides, cationically modified starch, cationically modifiedguar, polysiloxanes, poly diallyl dimethyl ammonium halides, copolymersof poly diallyl dimethyl ammonium chloride and vinyl pyrrolidone,acrylamides, imidazoles, imidazolinium halides, imidazolium halides,poly vinyl amine, copolymers of poly vinyl amine and N-vinyl formamideand mixtures thereof.

The deposition polymer typically has a weight average molecular weightof from 1,000 Da to 50,000,000 Da. The deposition polymer preferably hasa charge density of from 1 meq/g of the deposition polymer to 23 meq/gof the deposition polymer.

More preferably, the deposition polymer is selected from the groupconsisting of polyvinyl amines, polyvinyl formamides, and polyallylamines and copolymers thereof. Most preferably, the deposition polymeris a polyvinyl formamides. When the deposition polymer is a polyvinylformamide, the deposition polymer preferably has a degree of hydrolysisof from 5% to 95%. Examples of suitable coatings and processes forcoating microcapsules can be found in USPA 2011/0111999 (A1).

Preferably, at least 75%, 85% or even 90% of the perfume microcapsuleshave a particle size of from 1 microns to 80 microns, more preferablyfrom 5 microns to 60 microns, even more preferably from 10 microns to 50microns, most preferably from 15 microns to 40 microns.

Preferably, at least 75%, 85% or even 90% of the perfume microcapsuleshave a wall thickness of from 60 nm to 250 nm, more preferably from 80nm to 180 nm, even more preferably from 100 nm to 160 nm.

In order to raise the pH of the slurry to a pH of from 4 to 7,preferably from 5 to 5.5, an alkali agent can be added. Suitable alkaliagents include: sodium hydroxide, ammonia, and mixtures thereof.

The microcapsule core comprises an encapsulated perfume, the perfumecomprising a perfume raw material selected from the group consisting ofaldehydes, ketones, and mixtures thereof. Suitable perfume aldehydes andketones are those that provide an odour. Perfume raw materials areodoriferous materials which enhance the smell of a treated substrate.Non-limiting examples of perfumes, suitable for encapsulation intomicrocapsules, are described in US 2003-0104969 A1, paragraphs 46-81.Aldehydes and ketones having an odour detection threshold (ODT) of lessthan 1 ppm, preferably lower than 10 ppb, are preferred. A low odourdetection threshold results in lower levels of the aldehydes and ketonesbeing needed for providing the desired scent. The microcapsule core canalso comprise further perfume raw materials, depending on the desiredodour character. The choice of the perfume raw materials defines boththe odour intensity and character of the resultant perfume composition.

Preferably, the microcapsule core comprises from 0.1% to 100% by weightof the perfume. More preferably, the microcapsule core comprises from10% to 50%, even more preferably from 15% to 30% by weight of theperfume.

Preferably, the perfume comprised in the microcapsule core comprisesfrom 0.1% to 100%, more preferably from 0.5% to 75%, even morepreferably from 1% to 50% by weight of the perfume raw material selectedfrom the group consisting of: an aldehyde, a ketone, and mixturesthereof.

The perfume aldehydes and ketones, used in the slurries of the presentinvention, do not form complexes with urea, pyrogallol, or 1,2hexanediol, which discolour of the slurry.

The perfume aldehyde is preferably selected from the group consistingof: Ethyl vanillin [CAS number: 121-32-4], Triplal [CAS number:68039-49-6], Hexyl cinnamic aldehyde [CAS number: 101-86-0], Undecylenicaldehyde [CAS number: 112-45-8], Para tertiary butyl cinnamic aldehyde[CAS number: 80-54-6], Pinoacetaldehyde [CAS number: 33885-51-7], Pinylisobutyraldehyde [CAS number: 33885-52-8], Lyral [CAS number:31906-04-4], Hydrocintronellal [CAS number: 107-75-5], Methyl nonylacetaldehyde [CAS number: 110-41-8], Methyl octyl acetaldehyde [CASnumber: 19009-56-4], 2-[4-Methylphenyl)methylen]-heptanal [CAS number:84697-09-6], Amyl cinnamic aldehyde [CAS number: 7493-78-9], Nonylaldehyde [CAS number: 124-19-6], 2,6,10-trimethyl-9-undecenal [CASnumber: 141-13-9], Decyl aldehyde [CAS number: 112-31-2], Lauricaldehyde [CAS number: 112-54-9], Undecylic aldehyde [CAS number:1123-44-7], Cymal [CAS number: 103-95-7],2,4-dimethyl-3-cyclohexen-1-carbaldehyde [CAS number: 68039-49-6],3-(3-isopropylphenyl)butanal [CAS number: 125109-85-5], citral [CASnumber: 5392-40-5], 2,6-dimethyl-5-heptenal [CAS number: 106-72-9],p-tolylacetaldehyde [CAS number: 104-09-6], Anisic aldehyde [CAS number:123-11-5], vanillin [CAS number: 121-33-5],2-Methyl-3-(4-methoxyphenyl)propanal [CAS number: 5462-06-6],3-(pcumenyl)propionaldehyde [CAS number: 7775-00-0],3-(4-ethylphenyl)-2,2-dimethylpropanal [CAS number: 67634-14-4],3-(1,3-benzodioxol-5-yl)-2-methylpropanal [CAS number: 1205-17-0],Limonene aldehyde [CAS number: 6784-13-0],8,8-dimethyl-2,3,4,5,6,7-hexahydro-1H-naphthalene-2-carbaldehyde [CASnumber: 68991-97-9],1-methyl-3-(4-methylpent-3-enyl)cyclohex-3-ene-1-carbaldehyde [CASnumber: 52475-86-2], and mixtures thereof.

The perfume aldehyde is more preferably selected from the groupconsisting of: Ethyl Vanillin [CAS number: 121-32-4], Vanillin [CASnumber: 121-33-5], Triplal [CAS number: 68039-49-6], Hexyl CinnamicAldehyde [CAS number: 101-86-0], Amyl cinnamic aldehyde [CAS number:7493-78-9], decyl aldehyde [CAS number: 112-31-2], Cymal [CAS number:103-95-7], Anisic aldehyde [CAS number: 123-11-5], and mixtures thereof.

The perfume ketone is preferably selected from the group consisting of:Benzyl Acetone [CAS number: 2550-26-7], Alpha-Ionone [CAS number:12741-3], Beta-ionone [CAS number: 14901-07-6], Gamma methyl ionone [CASnumber: 127-51-5], isodamascone [CAS number: 39872-57-6],Alpha-Damascone [CAS number: 24720-09-0], Beta-damascone [CAS number:23726-91-2], Delta-damascone [CAS number: 57378-68-4], damascenone [CASnumber: 23696-85-7], Methyl cedryl ketone [CAS number: 32388-55-9],dihydrojasmone [CAS number: 11128-08-1], Hexyl cyclopentanone [CASnumber: 13074-65-2], 2-Heptyl cylopentanone [CAS number: 137-03-1],2-Pentyl-cyclopentanone [CAS number: 4819-67-4], 3-methyl-2-pentylcyclopentanone [CAS number: 13074-63-0], 2-hexylidene cyclopentanone[CAS number: 17373-86-6], 1-(5,5-Dimethyl-1-cyclohexenyl)pent-4-en-1-one[CAS number: 56973-85-4], Methyl-beta-Naphtyl ketone [CAS number:93-08-3], Beta-Napthyl Methyl Ether [CAS number: 93-04-9], 4-Methoxyacetophenone [CAS number: 100-06-1], 4-Methyl acetophenone [CAS number:122-06-1], Cashmeran [CAS number: 33704-61-9],4-(4-hydroxyphenyl)-2-butanone [CAS number: 5471-51-2], Menthone [CASnumber: 1074-95-9], 3,4,5,6,-pentamethyl-3-hepten-2-one [CAS number:81786-73-4], Cis-jasmone [CAS number: 488-10-8], Methyldihydrojasmonate[CAS number: 24851-98-7], Para methyl acetophenone [CAS number:122-00-9], 2-cyclohexyl-1,6-heptadien-3-one [CAS number: 313973-37-4],2,4,4,7-tetramethyl-oct-6-en3-one [CAS number: 74338-72-0], LaevoCarvone [CAS number: 6485-40-1], and mixtures thereof.

The perfume ketone is more preferably selected from the group consistingof: Benzyl Acetone [CAS number: 2550-26-7], Alpha-Ionone [CAS number:12741-3], Beta-ionone [CAS number: 14901-07-6], Gamma methyl ionone [CASnumber: 127-51-5], isodamascone [CAS number: 39872-57-6],Alpha-Damascone [CAS number: 24720-09-0], Beta-damascone [CAS number:23726-91-2], Delta-damascone [CAS number: 57378-68-4], Damascenone [CASnumber: 23696-85-7], Methyl cedryl ketone [CAS number: 32388-55-9],Dihydrojasmone [CAS number: 11128-08-1], Hexyl cyclopentanone [CASnumber: 13074-65-2], 2-Heptyl cylopentanone [CAS number: 137-03-1],2-Pentyl-cyclopentanone [CAS number: 4819-67-4], 3-methyl-2-pentylcyclopentanone [CAS number: 13074-63-0], 2-hexylidene cyclopentanone[CAS number: 17373-86-6], 1-(5,5-Dimethyl-1-cyclohexenyl)pent-4-en-1-one[CAS number: 56973-85-4], Methyl-beta-Naphtyl ketone [CAS number:93-08-3], Beta-Napthyl Methyl Ether [CAS number: 93-04-9], Para methylacetophenone [CAS number: 122-00-9], 2-cyclohexyl-1,6-heptadien-3-one[CAS number: 313973-37-4], 2,4,4,7-tetramethyl-oct-6-en3-one [CASnumber: 74338-72-0], Laevo Carvone [CAS number: 6485-40-1], and mixturesthereof.

Particularly preferred, are perfume aldehydes and ketones selected fromthe group consisting of: Triplal [CAS number: 68039-49-6], DecylAldehyde [CAS number: 112-31-2], Cymal [CAS number: 103-95-7],Undecylenic aldehyde [CAS number: 112-45-8], delta damascone [CASnumber: 57378-68-4], Gamma Methyl Ionone [CAS number: 127-51-5], andmixtures thereof.

Primary or Secondary Amine:

The treatment composition comprises at least one primary or secondaryamine. Suitable primary or secondary amines may be selected fromalkanolamines, polyamines, and mixtures thereof.

The term “primary or secondary amine”, means a compound which carries atleast one primary, or secondary amine functional moiety. Hence, primaryamines comprise at least one —NH2 group, and secondary amines compriseat least on —NH—R group, wherein R is not hydrogen. The primary orsecondary amine may also comprise both primary and secondary aminefunctional moieties. The formaldehyde scavengers of slurries of thepresent invention do not comprise activated methylene groups. Suchactivated methylene groups are able to react with primary and secondaryamines, and either an aldehyde or ketone, to form complexes which leadto discoloration of the treatment composition.

Alkanolamines are typically added to treatment compositions, as apH-adjusting agent, at a level of from 0.02% to 15%, preferably from0.5% to 10%, more preferably from 1% to 5% by weight of the treatmentcomposition. Suitable alkanolamines may be selected frommonoalkanolamines, dialkanolamines, and mixtures thereof. Loweralkanolamines, comprising from 1 to 3 carbon atoms per alkyl group, suchas monoethanolamine, diethanolamine, and mixtures thereof, arepreferred. Monoethanolamine is particularly preferred. Higheralkanolamines have higher molecular weight alkyl groups, and may be lessmass efficient for the purpose of pH adjustment.

The treatment composition may comprise a polyamine. When present, suchpolyamines are preferably present at a level of from 0.01% to 10%,preferably from 0.1% to 5%, more preferable from 0.2% to 3% by weight ofthe treatment composition of a polyamine.

Suitable polyamines are polymer molecules comprising at least oneprimary or secondary amine. Preferred polyamines have a weight averagemolecular weight of from 300 g/mol to 20,000,000 g/mol, preferably 500g/mol to 10,000,000 g/mol.

Suitable polyamines comprise: at least one primary amine, at least onesecondary amine, and combinations thereof, attached to a polymericbackbone. The polymeric backbone can be either inorganic, organic, andcombinations thereof. Primary amine functional moieties can be: graftedto the polymer backbone, form an endcap to the polymer backbone, andcombinations thereof. Secondary amine functional moieties can be:grafted to the polymer backbone, form an endcap to the polymer backbone,incorporated as part of the polymer backbone, and combinations thereof.The polymer backbone can be: linear, branched, dendritic, andcombinations thereof.

Preferred polyamines, comprising an inorganic polymer backbone, arethose selected from organosilicon polymers or organic-organosiliconcopolymers of amino derivatized organo silane, siloxane, silazane,alumane, aluminum siloxane, or aluminum silicate compounds. Morepreferred polyamines, comprising an inorganic polymer backbone are:organosiloxanes with at least one primary amine moiety, such as thediaminoalkylsiloxane [H₂NCH₂(CH₃)₂Si]O, or the organoaminosilane(C₆H₅)₃SiNH₂ described in: Chemistry and Technology of Silicone, W.Noll, Academic Press Inc. 1998, London, pp 209, 106).

Preferred polyamines, utilizing an organic polymeric backbone, are thoseselected from: polyethyleneimines, dendrimers comprising amines;polyvinylamines and derivatives thereof, and/or copolymer thereof;polyaminoacid and copolymers thereof; cross-linked polyaminoacids; aminosubstituted polyvinylalcohol; polyoxyethylene bis amine or bisaminoalkyl; and mixtures thereof.

Particularly preferred polyamines are polyethyleneimines comprising atleast one primary or secondary amine, such as those commerciallyavailable under the tradename Lupasol like Lupasol FG (MW 800), G20wfv(MW 1300), PR8515 (MW 2000), WF (MW 25000), FC (MW 800), G20 (MW 1300),G35 (MW 1200), G100 (MW 2000), HF (MW 25000), P (MW 750000), PS (MW750000), SK (MW 2000000), SNA (MW 1000000). Of these, the most preferredinclude Lupasol HF or WF (MW 25000), P (MW 750000), PS (MW 750000), SK(MW 2000000), 620wfv (MW 1300) and PR 1815 (MW 2000), Epomin SP-103,Epomin SP-110, Epomin SP-003, Epomin SP-006, Epomin SP-012, EpominSP-018, Epomin SP-200, and partially alkoxylated polyethyleneimine, suchas polyethyleneimine 80% ethoxylated from Aldrich.

Also preferred are dendrimers selected from the group consisting of:polyethyleneimine dendrimers; polypropylenimine dendrimers;polyamidoamine dendrimers; and mixtures thereof. Commercialpolyamidoamines (PAMAM) dendrimers are available under the tradenames:Starburst®, generation G0-G10 from Dendritech, and the Astromols®dendrimers generation 1-5 from DSM (being DiAminoButane PolyAmine DAB(PA)_(x) dendrimers with x=2^(n))(4 and n being generally comprisedbetween 0 and 4).

Suitable polyamines can also be selected from the group consisting of:polyvinylamine with a weight average MW of from 300 to 2,000,000;alkoxylated polyvinylamine with a weight average MW of from 600 to 3000and a degree of ethoxylation of from 0.2 to 0.8; polyvinylaminevinylalcohol—molar ratio 2:1, polyvinylamine vinylformamide—molar ratio1:2 and polyvinylamine vinylformamide-molar ratio 2:1;triethylenetetramine; diethylenetriamine; tetraethylenepentamine;bis-aminopropylpiperazine; polyamino acid (L-lysine/lauric acid in amolar ratio of 10/1); polyamino acid (L-lysine/aminocaproic acid/adipicacid in a molar ratio of 5/5/1); polyamino acid (L-lysine/aminocaproicacid/ethylhexanoic acid in a molar ratio of 5/3/1); polyamino acid(polylysine-cocaprolactam); polylysine; polylysine hydrobromide;cross-linked polylysine; amino substituted polyvinylalcohol with aweight average MW of from 400 to 300,000; polyoxyethylene bis[amine];polyoxyethylene bis[6-aminohexyl];N,N′-bis-(3-aminopropyl)-1,3-propanediamine linear or branched (TPTA);and 1,4-bis-(3-aminopropyl) piperazine (BNPP).

The more preferred primary or secondary amines are selected from:alkanolamines, ethyl-4-amino benzoate, polyethyleneimine polymerscommercially available under the tradename Lupasol, such as Lupasol HF,P, PS, SK, SNA, WF, G20wfv and PR8515; the diaminobutane dendrimersAstramol®, polylysine, cross-linked polylysine,N,N′-bis-(3-aminopropyl)-1,3-propanediamine linear or branched;1,4-bis-(3-aminopropyl) piperazine, and mixtures thereof. Most preferredprimary or secondary amines are those selected from: alkanolamines,ethyl-4-amino benzoate, polyethyleneimine polymers having a molecularweight greater than 200 Daltons, including those commercially availableunder the tradename Lupasol such as Lupasol HF, P, PS, SK, SNA, WF,G20wfv and PR8515; polylysine; cross-linked polylysine;N,N′-bis-(3-aminopropyl)-1,3-propanediamine, linear or branched;1,4-bis-(3-aminopropyl) piperazine; and mixtures thereof.

Formaldehyde Scavenger:

The microcapsules of the treatment composition, of the presentinvention, comprise a wall that is made by cross-linking formaldehydewith at least one other monomer. After the cross-linking reaction hasbeen completed, residual amounts of free formaldehyde remain. Furtherformaldehyde can be introduced with additional ingredients, such ascross-linking agents. In addition, formaldehyde is released as themicrocapsules age. Without wishing to be bound by theory, it is believedthat the free formaldehyde levels increase due to residual curing, andhydrolysis of the end-groups, in the cross-linked microcapsule wall.Therefore, a formaldehyde scavenger is added to the treatmentcomposition, to ensure the level of free formaldehyde remains atacceptable levels.

The term “free formaldehyde” means those molecular forms present inaqueous solution capable of rapid equilibration with the nativemolecule, i.e., H₂CO, in the headspace over the solution. This includesthe aqueous native molecule, its hydrated form (methylene glycolHOCH₂OH), and its polymerized hydrated form (HO(CH2O)_(n)H, wherein n isgreater than 1. These are described in detail in a monograph by J. F.Walker (Formaldehyde ACS Monograph Series No. 159 3rd Edition 1964Reinhold Publishing Corp.). The free formaldehyde level is measuredusing ASTM method D5910-05.

The treatment compositions of the present invention comprise aformaldehyde scavenger selected from the group consisting of: urea,pyrogallol, 1,2 hexanediol, and mixtures thereof. Derivatives of theaforementioned formaldehyde scavengers are not considered suitable foruse in the treatment compositions of the present invention.

The formaldehyde scavenger can be added directly to the treatmentcomposition, or as part of a premix. However, the formaldehyde scavengeris preferably incorporated into the microcapsule slurry which is, inturn, incorporated into the treatment composition. When the formaldehydescavenger is added via the microcapsule slurry, it has been found thatthe colour stability of the treatment composition is further enhanced.

The formaldehyde scavengers of the present invention do not compriseactivated methylene groups. Activated methylene groups have a methylenegroup between two strong electron withdrawing groups. Without wishing tobe bound by theory, it is believed that activated methylene groups canreact with aldehydes and ketones, resulting in coloured compounds whichdiscolour the treatment composition. The treatment composition maycomprise further formaldehyde scavengers. However, such furtherformaldehyde scavengers should also not comprise an activated methylenegroup. When present, the amount of formaldehyde scavenger comprising anactivated methylene group, which is present in the treatmentcomposition, is limited to less than 25%, more preferably less than 15%,most preferably less than 5% of the total level of formaldehydescavenger.

Urea is the most preferred formaldehyde scavenger. It is believed thatas well as being a formaldehyde scavenger, urea is able to undergo across-linking reaction with the polymeric wall of the microcapsules, andinhibit the release of free formaldehyde from the microcapsule wall.Hence, it is believed that urea can both reduce the generation of freeformaldehyde, and scavenge any formaldehyde that is released into theslurry or treatment composition. For instance, when the microcapsulewall is formed by cross-linking formaldehyde with melamine, it isbelieved that urea is able to react with the methylol groups of themelamine-formaldehyde polymeric wall, and inhibits the release of freeformaldehyde from the microcapsule wall. Moreover, when the ureacomplexes with the microcapsule wall, particularly walls made fromcrosslinking urea, melamine, and mixtures thereof with formaldehyde, thewall is made less porous. As a consequence, leakage of the perfume rawmaterials from the microcapsule core, including aldehydes and ketones,is reduced. When urea is used, the urea is preferably added directly tothe microcapsule slurry, which is in turn added to the treatmentcomposition. When urea is first added to the microcapsule slurry, whichis then added to the treatment composition, a pH of less than 5.5 isparticularly preferred for the microcapsule slurry, for improvedformaldehyde scavenging and microcapsule wall stability.

The formaldehyde scavenger is preferably added to the treatmentcomposition, in an excess amount relative to the free formaldehyde thatwould be present if no formaldehyde scavenger had been added. As such,the formaldehyde scavenger is preferably added at excess molarconcentrations of from 1:1 to 5:1, more preferably from 2:1 to 4:1, evenmore preferably from 2:1 to 5:2, most preferably from 5:2 to 5:1,relative to the amount of free formaldehyde that would be present in thetreatment composition if no formaldehyde scavenger were added. Theamount of free formaldehyde, that would be present in the treatmentcomposition, is determined in the absence of the formaldehyde scavenger.

The formaldehyde scavenger is preferably present at a level whichreduces free formaldehyde in the treatment composition to less than 50parts per million (ppm), more preferably to less than about 25 ppm, evenmore preferably to less than about 10 ppm. When the formaldehydescavenger is added directly to the microcapsule slurry, the formaldehydescavenger is preferably present at a level which reduces freeformaldehyde in the treatment composition to less than 50 parts permillion (ppm), more preferably to less than about 25 ppm, even morepreferably to less than about 10 ppm.

The formaldehyde scavenger is preferably present in the treatmentcomposition at a level of from 0.005% to 0.8%, more preferably from0.03% to 0.5%, most preferably from 0.065% to 0.25%, by weight of thetreatment composition.

If added directly to the microcapsule slurry, the formaldehyde scavengeris preferably present in the microcapsule slurry at a level of from0.01% to 12%, more preferably from 1% to 8%, most preferably from 2% to6%, by weight of the microcapsule slurry.

Method of Treatment:

The compositions of the present invention can be used in a method ofproviding an extended odour benefit to a situs, by contacting the situswith the treatment composition of the present invention. Typically, theextended odour benefit is the provision of a perfume odour benefit, uponrubbing the dried situs, after the fabric has been stored on a shelf for1 week, preferably 2 weeks, more preferably 4 weeks at 25° C., andwrapped in aluminium foil.

Preferably, the situs is a fabric. The fabric is preferably contactedwith the treatment composition in an automatic washing machine. Forinstance, when the treatment composition is a detergent composition, thefabric is contacted with the treatment composition during the wash cycleof the automatic washing machine. When the treatment composition is afabric softening composition, the fabric is contacted with the treatmentcomposition during a rinse cycle of the automatic washing machine.

Methods:

A) pH Measurement:

The pH is measured on the neat composition, at 25° C., using a SartariusPT-10P pH meter with gel-filled probe (such as the Toledo probe, partnumber 52 000 100), calibrated according to the instructions manual.

B) Odour Detection Threshold:

The odour detection threshold is measured at controlled GasChromatography (GC) conditions such as described here below. Thisparameter refers to the value commonly used in the perfumery arts andwhich is the lowest concentration at which significant detection takesplace that some odorous material is present. Please refer for example in“Compilation of Odor and Taste Threshold Value Data (ASTM DS 48 A)”,edited by F. A. Fazzalari, International Business Machines, HopwellJunction, N.Y. and in Calkin et al., Perfumery, Practice and Principles,John Willey & Sons, Inc., page 243 et seq (1994). For the purpose of thepresent invention, the odour Detection Threshold is measured accordingto the following method:

The gas chromatograph is characterized to determine the exact volume ofmaterial injected by the syringe, the precise split ratio, and thehydrocarbon response using a hydrocarbon standard of known concentrationand chain-length distribution. The air flow rate is accurately measuredand, assuming the duration of a human inhalation to last 0.02 minutes,the sampled volume is calculated. Since the precise concentration at thedetector at any point in time is known, the mass per volume inhaled isknown and hence the concentration of material. To determine the ODT of aperfume material, solutions are delivered to the sniff port at theback-calculated concentration. A panellist sniffs the GC effluent andidentifies the retention time when odour is noticed. The average overall panellists determines the threshold of noticeability. The necessaryamount of analyte is injected onto the column to achieve a certainconcentration, such as 10 ppb, at the detector. Typical gaschromatograph parameters for determining odour detection thresholds arelisted below:

-   -   GC: 5890 Series II with FID detector    -   7673 Autosampler    -   Column: J&W Scientific DB-1    -   Length 30 meters ID 0.25 mm film thickness 1 micron    -   Method:    -   Split Injection: 17/1 split ratio    -   Autosampler: 1.13 microliters per injection    -   Column Flow: 1.10 mL/minute    -   Air Flow: 345 mL/minute    -   Inlet Temp. 245° C.    -   Detector Temp. 285° C.    -   Temperature Information    -   Initial Temperature: 50° C.    -   Rate: 5 C/minute    -   Final Temperature: 280° C.    -   Final Time: 6 minutes    -   Leading assumptions: 0.02 minutes per sniff    -   GC air adds to sample dilution

EXAMPLES

Two slurries of perfume containing microcapsules were prepared, slurryA, of use in treatment compositions of the present invention, and slurryB, of use in comparative treatment compositions. The slurries were madeusing the same procedure, except that slurry A comprised 4 wt % urea asthe formaldehyde scavenger, and slurry B comprised 1.4 wt %acetoacetamide as the formaldehyde scavenger. Both slurries comprisedmicrocapsules of the same composition and structure. The microcapsulesof both slurries comprised walls that were formed by cross-linkingmelamine with formaldehyde. The microcapsules of both slurries werecoated with polyvinyl formamide. The core of the microcapsules of bothslurries consisted of the same perfume, comprising 39.2 wt % ofaldehydes.

Slurry A (of use in compositions Slurry B of the present invention)(comparative) wt % in slurry wt % in slurry Encapsulated perfume¹ 34 34Urea 4 — Acetoacetamide — 1.4 pH of slurry 5.3 5.3 Free formaldehydelevel <50 ppm <50 ppm ¹The encapsulated perfume comprised 39.2 wt % ofaldehydes

The slurries were incorporated into laundry treatment compositions, toform the following finished treatment compositions. Treatmentcomposition A comprised 0.035 wt % of urea. Treatment composition B(comparative) comprised 0.01 wt % of acetoacetamide. Both treatmentcompositions exhibited free formaldehyde levels of less than 1 ppm:

Treatment Treatment composi- composi- tion B tion A (comparative)Ingredient wt % wt % Alkylbenzene sulphonic acid 3.2 3.2 Sodium C12-15alkyl sulphate 4 4 Sodium C12-15 alkyl ethoxy 1.8 sulphate 10.3 10.3C12-14 alkyl 9-ethoxylate 0.66 0.66 C12-C14 alkyl dimethyl amine oxide0.9 0.9 C12-18 Fatty acid 1.5 1.5 Citric acid 1.8 1.8 Protease (PurafectPrime ®, 40.6 mg 1.3 1.3 active/g) Amylase (Natalase ®, 29.26 mgactive/g) 0.3 0.3 Diethylenetriamine penta carboxylic acid 0.5 0.5Brightener² 0.16 0.16 Borax 2.5 2.5 Polyethylenimine₆₀₀(EO)₂₄(PO)₁₆ ³0.83 0.83 Ethoxylated polyethylenimine⁴ 1.8 1.8 Solvents (1,2propanediol, ethanol), 7.1 7.1 stabilizers Sodium formate 0.2 0.2Hydrogenated castor oil derivative 0.14 0.14 structurant Unencapsulatedperfume⁵ 0.63 0.63 Slurry A 0.88 — Slurry B (comparative) — 0.88 Bluedye 0.015 0.015 Monoethanolamine 1.4 1.4 Water and minors Up to 100 Upto 100 NaOH, sufficient to provide formulation 8.2 8.2 pH of: Freeformaldehyde level <1 ppm <1 ppm ²Tinopal ® TAS-X B36 ³Sokalan PG640from BASF ⁴Polyethyleneimine (MW = 600) with 20 ethoxylate groups per—NH ⁵The unencapsulated perfume comprised 17.8 wt % of aldehydes andketones

200 ml of treatment compositions A and B (comparative) were sealed in375 ml glass jars, and the treatment compositions aged for 2 weeks at50° C. and 8 weeks at 35° C. The composition colour, before and afteraging, and the change in colour (ΔE) were measured using the followingprocedure:

A plastic cuvette (size 12.5×12.5×45 mm, made by BRAND, Cat No 7590 05)was filled with the treatment composition to be analysed, ensuring thatthe sample was free of bubbles. The color was measured with a HunterlabColor Quest XE, with the measurement done in Reflectance mode, underD65/10 light conditions, and a 9.5 mm aperture. The colour was measuredon the L a b scale for both the “fresh” treatment composition (measured1 hour after making and store at 21° C.), and the aged treatmentcompositions. The discoloration, expressed as the change in colour ΔE,was calculated from the L a b values using the following equation:ΔE=(ΔL²+Δa²+Δb²)^(1/2):

Treatment Treatment composition B composition A (comparative) IngredientΔE ΔE 2 weeks at 50° C. 2.1 10.9 8 weeks at 35° C. 7.8 11.7

As can be seen from the colour stability data, the discoloration wassubstantially less for treatment composition A, using urea as theformaldehyde scavenger, even though a much higher level of theformaldehyde scavenger was used, in comparison to the acetoacetamideformaldehyde scavenger of comparative treatment composition B.

Examples C to H Liquid Laundry Treatment Compositions

Non-limiting examples of treatment compositions, of the presentinvention, comprising microcapsules having a microcapsule wall, formedfrom cross-linking melamine and formaldehyde, and a core comprising analdehyde or ketone containing perfume, and a formaldehyde scavengerselected from urea, pyrogallol, and 1,2 hexanediol are disclosed in thetable below:

C D E F G H Ingredient wt % wt % wt % wt % wt % wt % Sodium C12-15 alkylethoxy 1.8 — 0.50 12.0 12.0 6.0 7.0 sulphate Dodecyl Benzene SulphonicAcid 8.0 8.0 1.0 1.0 2.0 3.0 C12-14 alkyl 9-ethoxylate 8.0 6.0 5.0 7.05.0 3.0 Citric Acid 5.0 3.0 3.0 5.0 2.0 3.0 C12-18 Fatty acid 3.0 5.05.0 3.0 6.0 5.0 Ethoxy sulphated hexamethylene 1.9 1.2 1.5 2.0 1.0 1.0diamine quaternized Diethylene triamine penta 0.3 0.2 0.2 0.3 0.1 0.2methylene phosphonic acid Enzymes⁶ 1.20 0.80 — 1.2 0 0.8 Fluorescentbrightener⁷ 0.14 0.09 — 0.14 0.01 0.09 Cationic hydroxyethyl cellulose —— 0.10 — 0.200 0.30 Poly(acrylamide-co- — — 0 0.50 0.10 —diallyldimethylammonium chloride) Hydrogenated Castor Oil 0.50 0.44 0.20.2 0.3 0.3 Structurant Boric acid 2.4 1.5 1.0 2.4 1.0 1.5 Ethanol 0.501.0 2.0 2.0 1.0 1.0 1,2 propanediol 2.0 3.0 1.0 1.0 0.01 0.01Diethyleneglycol (DEG) 1.6 — — — — — 2,3-Methyl-1,3-propanediol (Mpdiol)1.0 1.0 — — — — Monoethanolamine 1.0 0.5 — — — — NaOH, sufficient toprovide pH 8 pH 8 pH 8 pH 8 pH 8 pH 8 formulation pH of: Sodium CumeneSulphonate 2.00 — — — — — (NaCS) Silicone (PDMS) emulsion 0.003 0.0030.003 0.003 0.003 0.003 Unencapsulated perfume 0.7 0.5 0.8 0.8 0.6 0.6Polyethylenimine ₆₀₀(EO)₂₄(PO)₁₆ ³ 0.01 0.10 0.00 0.10 0.20 0.05 PerfumeMicrocapsules slurry⁸ 1.00 5.00 1.00 2.00 0.10 0.80 Urea⁹ 0.06 0.2 — — —— Pyrogallol⁹ — — 0.05 0.14 — — 1,2 hexanediol⁹ — — — — 0.005 0.056Water Balance Balance Balance Balance Balance Balance to to to to to to100% 100% 100% 100% 100% 100% ⁶Natalase ®, Mannaway ® and Whitezyme ®,all products of Novozymes, Bagsvaerd, Denmark. ⁷Fluorescent brightenercan be anyone of Tinopa ® AMS-GX, Tinopal ® CBS-X or Tinopal ® TAS-XB36, or mixtures thereof, all supplied by Ciba Specialty Chemicals,Basel, Switzerland ⁸A perfume microcapsule slurry comprising 35 wt % ofmicrocapsules, the microcapsules having a wall formed from cross-linkingmelamine and formaldehyde, and comprising an aldehyde or ketonecontaining perfume. ⁹Added either directly to the liquid laundrytreatment composition, or to the microcapsule slurry, which is in turn,added to the treatment composition.

Non-limiting examples of low water treatment compositions, of thepresent invention, comprising the aforementioned microcapsules, and ureaas a formaldehyde scavenger are disclosed in the table below:

Treatment Treatment Treatment composi- composi- composi- tion I tion Jtion K Ingredient wt % wt % wt % Linear Alkylbenzene sulfonic acid 15 1719 C12-14 alkyl ethoxy 3 sulfonic acid 7 8 — C12-15 alkyl ethoxy 2sulfonic acid — — 9 C14-15 alkyl 7-ethoxylate — 14 — C12-14 alkyl7-ethoxylate 12 — — C12-14 alkyl-9-ethoxylate — — 15 C12-18 Fatty acid15 17 5 Citric acid 0.7 0.5 0.8 Ethoxylated polyethylenimine⁴ 4 — 7Hydroxyethane diphosphonic acid 1.2 — — Diethylenetriamine Pentaaceticacid — — 0.6 Ethylenediaminediscuccinic acid — — 0.6 FluorescentWhitening Agent 0.2 0.4 0.2 1,2 Propanediol 16 12 14 Glycerol 6 8 5Diethyleneglycol — — 2 Hydrogenated castor oil (structurant) 0.15 0.25 —Unencapsulated perfume 2.0 1.5 1.7 Perfume Microcapsules slurry⁸ 0.3 1.48 Urea⁹ 0.012 0.084 0.64 Monoethanolamine Up to Up to Up to pH 8 pH 8 pH8 Protease enzyme⁶ 0.05 0.075 0.12 Amylase enzyme 0.005 — 0.01 Mannanaseenzyme⁶ 0.01 — 0.005 Xyloglucanase — — 0.005 Water 10 8 9 Minors(antifoam, aesthetics, To 100 To 100 To 100 stabilizers etc.) partsparts parts

The resultant low water treatment compositions can be encapsulated inwater-soluble film, to form water-soluble unit-dose articles.

The dimensions and values disclosed herein are not to be understood asbeing strictly limited to the exact numerical values recited. Instead,unless otherwise specified, each such dimension is intended to mean boththe recited value and a functionally equivalent range surrounding thatvalue. For example, a dimension disclosed as “40 mm” is intended to mean“about 40 mm”.

Every document cited herein, including any cross referenced or relatedpatent or application, is hereby incorporated herein by reference in itsentirety unless expressly excluded or otherwise limited. The citation ofany document is not an admission that it is prior art with respect toany invention disclosed or claimed herein or that it alone, or in anycombination with any other reference or references, teaches, suggests ordiscloses any such invention. Further, to the extent that any meaning ordefinition of a term in this document conflicts with any meaning ordefinition of the same term in a document incorporated by reference, themeaning or definition assigned to that term in this document shallgovern.

While particular embodiments of the present invention have beenillustrated and described, it would be obvious to those skilled in theart that various other changes and modifications can be made withoutdeparting from the spirit and scope of the invention. It is thereforeintended to cover in the appended claims all such changes andmodifications that are within the scope of this invention.

What is claimed is:
 1. A treatment composition comprising: (a)microcapsules, the microcapsules comprising a microcapsule core and amicrocapsule wall which encapsulates the microcapsule core, wherein (i)the microcapsule wall is formed by cross-linking formaldehyde with atleast one other monomer; and (ii) the microcapsule core comprises aperfume, the perfume comprising a perfume raw material selected from thegroup consisting of aldehydes, ketones, and mixtures thereof; (b) aprimary or secondary amine; (c) a formaldehyde scavenger consisting ofurea, wherein the formaldehyde scavenger is present in the treatmentcomposition at a level of from 0.035% to 0.8% by weight of the treatmentcomposition; (d) a non-fabric substantive dye, wherein the non-fabricsubstantive dye comprises blue dye.
 2. The treatment compositionaccording to claim 1, wherein the at least one other monomer of themicrocapsule wall is selected from the group consisting of: melamine,urea, glycouril, benzoguanine, dihydroxyethyleneurea, hydroxy (alkoxy)alkyleneurea monomers, and mixtures thereof.
 3. The treatmentcomposition according to claim 1, wherein the treatment compositioncomprises the microcapsules at a level of from about 0.01 wt % to about12.5 wt % by weight of the treatment composition.
 4. The treatmentcomposition according to claim 1, wherein the perfume comprised in themicrocapsule core comprises from 0.1% to 100% by weight of the perfumeraw material selected from the group consisting of: an aldehyde, aketone, and mixtures thereof.
 5. The treatment composition according toclaim 1, wherein the perfume raw material selected from: (a) a perfumealdehyde selected from the group consisting of: Ethyl vanillin [CASnumber: 121-32-4], Triplal [CAS number: 68039-49-6], Hexyl cinnamicaldehyde [CAS number: 101-86-0], Undecylenic aldehyde [CAS number:112-45-8], Para tertiary butyl cinnamic aldehyde [CAS number: 80-54-6],Pinoacetaldehyde [CAS number: 33885-51-7], Pinyl isobutyraldehyde [CASnumber: 33885-52-8], Lyral [CAS number: 31906-04-4], Hydrocintronellal[CAS number: 107-75-5], Methyl nonyl acetaldehyde [CAS number:110-41-8], Methyl octyl acetaldehyde [CAS number: 19009-56-4],2-[4-Methylphenyl)methylen]-heptanal [CAS number: 84697-09-6], Amylcinnamic aldehyde [CAS number: 7493-78-9], Nonyl aldehyde [CAS number:124-19-6], 2,6,10-trimethyl-9-undecenal [CAS number: 141-13-9], Decylaldehyde [CAS number: 112-31-2], Lauric aldehyde [CAS number: 112-54-9],Undecylic aldehyde [CAS number: 1123-44-7], Cymal [CAS number:103-95-7], 2,4-dimethyl-3-cyclohexen-1-carbaldehyde [CAS number:68039-49-6], 3-(3-isopropylphenyl)butanal [CAS number: 125109-85-5],citral [CAS number: 5392-40-5], 2,6-dimethyl-5-heptenal [CAS number:106-72-9], p-tolylacetaldehyde [CAS number: 104-09-6], Anisic aldehyde[CAS number: 123-11-5], vanillin [CAS number: 121-33-5],2-Methyl-3-(4-methoxyphenyl)propanal [CAS number: 5462-06-6],3-(pcumenyl)propionaldehyde [CAS number: 7775-00-0],3-(4-ethylphenyl)-2,2-dimethylpropanal [CAS number: 67634-14-4],3-(1,3-benzodioxol-5-yl)-2-methylpropanal [CAS number: 1205-17-0],Limonene aldehyde [CAS number: 6784-13-0],8,8-dimethyl-2,3,4,5,6,7-hexahydro-1H-naphthalene-2-carbaldehyde [CASnumber: 68991-97-9],1-methyl-3-(4-methylpent-3-enyl)cyclohex-3-ene-1-carbaldehyde [CASnumber: 52475-86-2], and mixtures thereof; (b) a perfume ketone selectedfrom the group consisting of: Benzyl Acetone [CAS number: 2550-26-7],Alpha-Ionone [CAS number: 12741-3], Beta-ionone [CAS number:14901-07-6], Gamma methyl ionone [CAS number: 127-51-5], isodamascone[CAS number: 39872-57-6], Alpha-Damascone [CAS number: 24720-09-0],Beta-damascone [CAS number: 23726-91-2], Delta-damascone [CAS number:57378-68-4], Damascenone [CAS number: 23696-85-7], Methyl cedryl ketone[CAS number: 32388-55-9], Dihydrojasmone [CAS number: 11128-08-1], Hexylcyclopentanone [CAS number: 13074-65-2], 2-Heptyl cylopentanone [CASnumber: 137-03-1], 2-Pentyl-cyclopentanone [CAS number: 4819-67-4],3-methyl-2-pentyl cyclopentanone [CAS number: 13074-63-0], 2-hexylidenecyclopentanone [CAS number: 17373-86-6],1-(5,5-Dimethyl-1-cyclohexenyl)pent-4-en-1-one [CAS number: 56973-85-4],Methyl-beta-Naphtyl ketone [CAS number: 93-08-3], Beta-Napthyl MethylEther [CAS number: 93-04-9], 4-Methoxy acetophenone [CAS number:100-06-1], 4-Methyl acetophenone [CAS number: 122-06-1], Cashmeran [CASnumber: 33704-61-9], 4-(4-hydroxyphenyl)-2-butanone [CAS number:5471-51-2], Menthone [CAS number: 1074-95-9],3,4,5,6,-pentamethyl-3-hepten-2-one [CAS number: 81786-73-4],Cis-jasmone [CAS number: 488-10-8], Methyldihydrojasmonate [CAS number:24851-98-7], Para methyl acetophenone [CAS number: 122-00-9],2-cyclohexyl-1,6-heptadien-3-one [CAS number: 313973-37-4],2,4,4,7-tetramethyl-oct-6-en3-one [CAS number: 74338-72-0], LaevoCarvone [CAS number: 6485-40-1], and mixtures thereof; and (c) mixturesthereof.
 6. The treatment composition according to claim 1, wherein thetreatment composition is a fabric treatment composition selected fromthe group consisting of: laundry detergent composition, fabric softeningcomposition, and combinations thereof.
 7. The treatment compositionaccording to claim 1, wherein the treatment composition furthercomprises an unencapsulated perfume composition.
 8. The treatmentcomposition according to claim 7, wherein the unencapsulated perfumecomposition comprises a perfume raw material selected from the groupconsisting of: an aldehyde, a ketone, and mixtures thereof.
 9. Thetreatment composition according to claim 1, wherein the treatmentcomposition further comprises a polyamine.
 10. A packaged productcomprising the treatment composition according to claim 1, containedwithin a transparent or translucent container.
 11. A method of providingan extended odour benefit to a situs, comprising the step of contactingthe situs with a treatment composition according to claim
 1. 12. Amethod according to claim 11, wherein the situs is a fabric, and thefabric is optionally contacted with the treatment composition in anautomatic washing machine.
 13. A treatment composition according toclaim 1, wherein the composition comprises the formaldehyde scavenger atexcess molar concentrations of from 1:1 to 5:1, relative to the amountof free formaldehyde that would be present in the treatment compositionif no formaldehyde scavenger were added.
 14. A treatment compositionaccording to claim 1, wherein said primary or secondary amine comprisesa polyethyleneimine.
 15. A unit dose article, comprising a treatmentcomposition according to claim 1, wherein the treatment compositioncomprises less than 20% by weight of water, and the treatmentcomposition is enclosed in a water-soluble or dispersible film.
 16. Apackaged product comprising the unit dose article according to claim 15,contained within a transparent or translucent container.
 17. A methodfor preventing discoloration in a treatment composition comprisingmicrocapsules, comprising the steps of: a) providing a compositioncomprising microcapsules, the microcapsules comprising a microcapsulecore and a microcapsule wall which encapsulates the microcapsule core,wherein: (i) the microcapsule wall is formed by cross-linkingformaldehyde with at least one other monomer; and (ii) the microcapsulecore comprises a perfume, the perfume comprising a perfume raw materialselected from the group consisting of aldehydes, ketones, and mixturesthereof; and b) combining the composition with a formaldehyde scavengerconsisting of urea, thereby forming a treatment composition, wherein theformaldehyde scavenger is present in the treatment composition at alevel of from 0.035% to 0.8% by weight of the treatment composition;wherein the treatment composition further comprises a non-fabricsubstantive dye that comprises blue dye.